The transcriptional co-factor RIP140 regulates mammary gland development by promoting the generation of key mitogenic signals

Jaya Nautiyal1, Jennifer H. Steel1, Meritxell Rosell Mane1, Olayiwola Oduwole1, Ariel Poliandri1, Xanthippi Alexi2, Nicholas Wood1, Matti Poutanen2, Wilbert Zwart3, John Stingl4 and Malcolm G. Parker1,*

SUMMARY
Nuclear receptor interacting protein (Nrip1), also known as RIP140, is a co-regulator for nuclear receptors that plays an essential role in ovulation by regulating the expression of the epidermal growth factor-like family of growth factors. Although several studies indicate a role for RIP140 in breast cancer, its role in the development of the mammary gland is unclear. By using RIP140-null and RIP140 transgenic mice, we demonstrate that RIP140 is an essential factor for normal mammary gland development and that it functions by mediating oestrogen signalling. RIP140-null mice exhibit minimal ductal elongation with no side-branching, whereas RIP140-overexpressing mice show increased cell proliferation and ductal branching with age. Tissue recombination experiments demonstrate that RIP140 expression is required in both the mammary epithelial and stromal compartments for ductal elongation during puberty and that loss of RIP140 leads to a catastrophic loss of the mammary epithelium, whereas RIP140 overexpression augments the mammary basal cell population and shifts the progenitor/differentiated cell balance within the luminal cell compartment towards the progenitors. For the first time, we present a genome-wide global view of oestrogen receptor-α (ERα) binding events in the developing mammary gland, which unravels 881 ERα binding sites. Unbiased evaluation of several ERα binding sites for RIP140 co-occupancy reveals selectivity and demonstrates that RIP140 acts as a co-regulator with ERα to regulate directly the expression of amphiregulin (Areg), the progesterone receptor (Pgr) and signal transducer and activator of transcription 5α (Stat5α), factors that influence key mitogenic pathways that regulate normal mammary gland development.

KEY WORDS: Amphiregulin, Mammary gland, Mammary progenitors, Oestrogen receptor, Progesterone receptor, RIP140, Mouse

INTRODUCTION
The development of the mouse mammary epithelium is regulated by female reproductive hormones, including oestrogen, progesterone and prolactin, together with their downstream paracrine effectors (Briskien and O’Malley, 2010; McNally and Martin, 2011). At birth, the mammary epithelium is composed of a rudimentary ductal system but at the onset of puberty the increased levels of circulating oestrogen promote the elongation of these ducts. This growth is marked by bulb-like structures called terminal end buds (TEBs), which are located at the distal tips of the growing ducts and are highly proliferative (Hinck and Silberstein, 2005). By 8–10 weeks of age, a well-formed epithelial network fills the mammary fat pad. Secondary and tertiary branching, which is under the influence of progesterone (Lydon et al., 1995), increases the complexity of the ductal tree with each oestrus cycle. During pregnancy, prolactin and progesterone promote the budding and expansion of alveoli (lobules) from the existing ductal network and the cells lining these alveoli synthesise and secrete milk during lactation (Gjorevski and Nelson, 2011).

Oestrogen, bound to oestrogen receptor-α (ERα; Esr1 – Mouse Genome Informatics), promotes ductal elongation during puberty. One of the most rapid changes induced by oestrogen is the induction of Areg, which is an important paracrine mediator required for ductal elongation. Areg knockout (KO) mice phenocopy ER KO mice as ablation of either gene results in severely impaired ductal development during puberty (Bocchinfuso et al., 2000; Mallepell et al., 2006; Ciarloni et al., 2007). Tissue recombination experiments and gene knockout mouse models indicate that Areg generated in the ovary, RIP140 as a co-factor for ERα (Egfr) in the stroma, which, as a feedback mechanism, promotes the synthesis of stromal growth-promoting factors (Sternlicht et al., 2005). Thus, signalling cross-talk between the mammary epithelium and stroma plays a crucial role in the development of the mammary gland.

We identified RIP140 as a co-factor for ERα in a breast cancer cell line (Cavaillé et al., 1994; Cavaillé et al., 1995), but subsequently found it interacts with other transcription factors, including many nuclear receptors (L’Horset et al., 1996; Heery et al., 1997). RIP140 is a pleiotropic co-factor that regulates energy homeostasis (Leonardsson et al., 2004; Herzog et al., 2007; Seth et al., 2007) and plays an essential role in ovulation (White et al., 2000; Tullet et al., 2005). Its function seems to vary according to its physiological role, serving as a co-repressor of catabolic gene expression (Christian et al., 2005; Seth et al., 2007) but as a co-activator of inflammatory gene expression (Zschiedrich et al., 2008; Nautiyal et al., 2010). In the ovary, RIP140 is required for the expression of the epidermal growth factor (EGF)-like family of growth factors, including Areg, amphiregulin...
(Ereg) and betacellulin (Btc), all of which are essential for cumulus expansion in response to the luteinizing hormone surge (Tullet et al., 2005; Nautiyal et al., 2010).

Preliminary experiments suggest that RIP140 might have a role in breast cancer. It appears that RIP140 mRNA expression is elevated in ductal carcinoma in situ (Lee et al., 2007; Hannafon et al., 2011) and varies with tumour subtype (Oh et al., 2006; Docquier et al., 2010), with higher RIP140 mRNA levels in luminal-like tumours than in basal-like tumours. This pattern is consistent with the pattern of Erα expression, and earlier work suggests that RIP140 expression is elevated in tamoxifen-resistant breast cancer cells (Chan et al., 1999). Given the potential involvement of RIP140 in breast cancer and its crucial role in the regulation of ovarian expression of Areg, we investigated the role of RIP140 in mammary gland development. Analysis of RIP140 null (RIP140 KO) and overexpressing transgenic (RIP140 Tg) mice indicates that RIP140 is an essential factor required for mammary gland development and that its expression is essential in both the epithelium and the stroma in order to influence glandular development. Furthermore, RIP140 is recruited together with Erα to the promoters/enhancers of a number of regulatory genes, including Areg, Pgr and Stat5a, thereby stimulating their transcription and thus regulating mammary gland development.

MATERIALS AND METHODS

Animals

The generation of RIP140-null animals (RIP140 KO) has been described previously (White et al., 2000). The mice used in this study were backcrossed eight generations to the C57BL/6 background. To generate mice overexpressing RIP140 (RIP140 Tg), human RIP140 (hRIP140; NRIP1 – Human Gene Nomenclature Database) was inserted in FVB/N background using a pCAGGS-hRIP construct (Frith et al., 2010). All animal studies were carried out in accordance with the UK Home Office guidelines. For tissue recombinant experiments, 3-week-old C57BL/6 and FVB/N wild-type (WT) mice were bought from Harlan Laboratories, UK. To examine the effect of oestradiol (E2) on mammary gland development, 21-day-old WT and RIP140 KO animals were ovariectomised and implanted with 21-day slow release pellets of E2 or placebo (0.025 mg/pellet, Innovative Research of America, FL, USA). After 21 days, the inguinal glands were excised for whole-mount staining. Uterine weight was taken to analyse the response to the hormone.

Blood collection and hormonal measurements

Mice were anaesthetised with tribromoethanol (Sigma-Aldrich, St Louis, MO, USA) by intraperitoneal injection and blood was withdrawn from the heart followed by cervical dislocation. Serum was separated by centrifugation from blood and stored at –20°C until used for oestradiol (E2) and prolactin (PRL) assays. E2 was analysed after diethyl ether extraction using a solid-phase time-resolved fluoroimmunoassay (PerkinElmer, Waltham, MA, USA) and implanted with 21-day slow release pellets of E2 or placebo (0.025 mg/pellet, Innovative Research of America, FL, USA). After 21 days, the inguinal glands were excised for whole-mount staining. Uterine weight was taken to analyse the response to the hormone.

Mammary gland whole-mounts

Inguinal mammary glands were dissected, spread onto a glass slide and fixed in a mixture of glacial acetic acid and ethanol (1:3) overnight. Tissue was then hydrated and stained in carmine alun stain. Whole-mounts were dehydrated in graded ethanol solutions, followed by clearing in Histoclear (National Diagnostics, Atlanta, GA, USA) and mounting in DPX (VWR Radnor, PA, USA). Digital pictures were taken using a Nikon Eclipse E600 (Nikon, Tokyo, Japan) and images stitched together using Lucia stitching software (Lucia Cytogetenics, Prague, Czech Republic).

Quantitative real-time PCR (Q-PCR)

Total RNA was isolated using TRIzol reagent (Sigma Aldrich) and treated with DNase I (Invitrogen, Carlsbad, CA, USA). RNA was prepared from sorted cells using the Pico Pure RNA Extraction Kit (Applied BioSystems, Warrington, UK) followed by DNase treatment using the RNase-free DNase set (Qiagen, Valencia, CA, USA). cDNA was synthesised using the Super Script First Strand Synthesis Kit (Invitrogen) according to the manufacturer’s instructions. Real-time PCR was performed using Opticon-2 (MJ Research, Watertown, MA, USA) and the SYBR Green Jumpstart Taq Ready Mix (Sigma-Aldrich) and gene-specific primers (supplementary material Table S1). Expression of all genes was normalised against the expression of ribosomal coding gene Rpl17.

Western blotting

Protein extracts (30 μg) were resolved by SDS-PAGE (4-12% gels, Invitrogen) and transferred to PVDF membranes (Millipore, Billerica, MA, USA). After blocking in 5% milk in Tris-buffered saline and 0.05% Tween 20 (TBST), blots were probed with primary antibodies and horseradish peroxidase-linked anti-mouse, -rat or -rabbit antibodies (Dako, Cambridge, UK), diluted 1:5000. After three or four washes in TBST, the bound antibodies were visualised using ECL substrate (Pierce, Rockford, IL, USA). The dilutions used for the primary antibodies were: Erα, 1:1000 (MC 200 sc-542, Santa Cruz, CA, USA); Areg, 1:2000 (MAB989, R&D Systems); progesterone receptor, 1:5000 (NCL-PGR-312, Leica, Wetzlar, Germany); cyclin D1, 1:1000 (# 2926, Cell Signaling, Danvers, MA, USA); Gata3, 1:1000 (sc-268, Santa Cruz) and Gapdh, 1:5000 (Mab-374, Millipore).

Immunohistochemistry

Mammary gland tissue was dissected and fixed in neutral buffered formalin for 24 hours, dehydrated as described for whole-mounts and embedded in paraffin. Paraffin sections (5 μm) were mounted on polylysine slides (VWR) and de-waxed before immunostaining using the Vectastain Elite ABC Kit (Vector Laboratories, Burlingame, CA, USA) and ImmPACT DAB Substrate Kit (Vector Laboratories). Primary antibodies were as follows: RIP140 (6D7, in-house monoclonal; 1:500) (Nautiyal et al., 2010), ERα (sc-542, Santa Cruz; 1:1000), Ki67 (Clone TEC-3, M7249, Dako; 1:100) and RANKL (AF462, R&D Systems; 1:100).

Quantification of hyper budding and Ki67 staining

Epithelial budding in mammary glands derived from 5-week-old mice or tissue recombinants for analysing pubertal growth was quantified by taking whole-mount images (2× magnification) and counting the number of epithelial buds manually. Budding in adult mammary glands was quantified by counting the number of epithelial buds in representative Haematoxylin and Eosin (H&E)-stained sections of the glands (10× magnification). Ki67-positive cells among total epithelial cells were counted manually in representative immunostained tissue sections (50× magnification).

Chromatin immunoprecipitation assay (ChiP)

At least six pairs of mammary gland pads from mice at 5-6 weeks of age were excised, washed with PBS and minced. The tissue was incubated with a solution of Gentle Collagenase/Hyaluronidase (StemCell Technologies, Vancouver, Canada) for 30 minutes at 37°C with agitation. After digestion, cell suspensions were filtered with a 100 μM pore strainer (BD Biosciences, San Jose, CA, USA) in order to eliminate any undigested tissue and were centrifuged for 10 minutes at 2000 rpm (400 g). The pellet, consisting of stromal and epithelial cells, was washed twice with PBS and fixed with 1% formaldehyde [15 minutes at room temperature (RT)]. The cross-linking reaction was stopped by adding 125 mM glycine for 5 minutes at RT. Cells were pelleted and washed again with PBS and resuspended in 10% SDS cell lysis buffer. Homogenate was then sonicated to get DNA fragments of 500 bp length. The ChIP assay was performed as described previously (Nautiyal et al., 2010). Specific proteins were immunoprecipitated with Dynabeads (Invitrogen) using mouse IgG (sc-2025, Santa Cruz), rabbit IgG (sc-2027 Santa Cruz), an ERα antibody (sc-543, Santa Cruz) and a validated RIP140 antibody for ChIP (Nautiyal et al., 2010). Enrichment relative to input was determined by Q-PCR. All Q-PCR reactions were carried out in duplicate. For primer sequences see supplementary material Table S1.

Solexa sequencing and enrichment analysis

ChiP DNA was amplified as described (Schmidt et al., 2009). Sequences were generated by the Illumina HiSeq 2000 genome analyser (using 50 bp reads), and aligned to the Mouse Reference Genome (mm9; July 2007).
Enriched regions of the genome were identified by comparing the ChIP sample with input using the MACS peak caller (Zhang et al., 2008) version 1.3.7.1. ChIP-Seq data have been deposited with NCBI GEO under accession number GSE43415.

Motif analysis, heatmaps and genomic distributions of binding events
ChIP-seq data snapshots were generated using the Integrative Genome Viewer IGV 2.1 (www.broadinstitute.org/igv/). Motif analysis was performed through Cistrome (cistrome.org), applying the SeqPos motif tool (He et al., 2010). The genomic distributions of binding sites were analysed using the cis-regulatory element annotation system (CEAS) (Ji et al., 2006). The genes closest to the binding site on both strands were analysed. If the binding region is within a gene, CEAS software indicates whether it is a 5′UTR, a 3′UTR, a coding exon or an intron. Promoter is defined as 3 kb upstream from RefSeq 5′ start. If a binding site is >3 kb away from the RefSeq transcription start site, it is considered to be distal intergenic.

Preparation of mammary cell suspensions
Single mammary cell suspensions were generated by dissecting out the fourth (inguinal) mammary gland from mature 8- to 12-week-old virgin female mice and incubating them overnight in DMEM (GIBCO) supplemented with 1× Gentle Collagenase/Hyaluronidase. Glands were then triturated with a p1000 pipette, washed and then treated with NH4Cl (StemCell Technologies) to lyse red blood cells. After washing, cells were sequentially incubated with 0.25% trypsin (StemCell Technologies) then 5 mg/ml dispase (StemCell Technologies) supplemented with 0.1 mg/ml DNase (Roche, West Sussex, UK), and then filtered through 40 μm mesh (BD Biosciences). Cells at this stage were either seeded into colony-forming assays or prepared for flow cytometry.

Flow cytometry
Single cells suspensions were blocked in 10% normal rat serum (Sigma Aldrich) diluted in Hank’s Balanced Salt Solution supplemented with 10 mM HEPES and 2% foetal bovine serum (FBS) (referred to as HF). Anti-CD45, -CD31, -BP-1 and -Ter119 antibodies (eBioscience, San Diego, CA, USA) were used to label haematopoietic, endothelial and some stromal cells. All antibodies were diluted in HF and all incubations from the remaining non-depleted stromal cells. Anti CD49b-PE (0.5 μg/ml, Biolegend) were used to identify the mammary epithelial cell populations.

RESULTS
RIP140 regulates ductal morphogenesis in the mammary gland
To study the role played by RIP140 in mammary gland development, we prepared mammary gland whole-mounts from 24-day-old, 5-week-old and 12-week-old WT and RIP140 KO mice. These time points represent pre-pubertal, pubertal and mature stages of mammary gland development, respectively. A rudimentary epithelium was observed at 24 days in both WT (Fig. 1A,A′) and RIP140 KO (Fig. 1B,B′) animals with no apparent differences in branching. At 5 weeks, the developing mammary tree had invaded approximately half the fat pad of WT mice with TEBs at the tips of the ducts (Fig. 1C,C′), but this was not apparent in RIP140 KO mice (Fig. 1D,D′). By 12 weeks, the mammary tree had filled the entire fat pad with extensive branching in WT mice (Fig. 1E,E′) but RIP140 KO mice exhibited a minimal ductal network (Fig. 1F,F′), indicating an essential role for
RIP140 in mammary gland development. The mammary tree in the RIP140 KO mice did eventually fill the fat pad by 5 months of age, but the ductal network was sparse relative to that in heterozygous and WT mice (supplementary material Fig. S1).

To examine the influence of overexpression of RIP140 (supplementary material Fig. S2A,B), we compared whole-mounts from aged-matched 3-, 4- and 5-month-old RIP140 Tg and WT mice. RIP140 Tg mice (Fig. 2B,D,F) developed numerous alveolar bud-like structures that became more extensive with age and the ductal network became more branched compared with the WT animals (Fig. 2A,G; supplementary material Fig. S3). By 4-5 months, the mammary glands in RIP140 Tg mice contained distended primary ducts (Fig. 2F), areas of hyperplastic growth (Fig. 2I), TEB-like structures (Fig. 2J) and structures with multiple cell layers (Fig. 2K); none of these features was present in the WT mammary epithelium (Fig. 2H). There was a marked increase in the proportion of proliferating (Ki67+) cells in mammary glands from RIP140 Tg mice compared with WT mice and the level of proliferation in RIP140 Tg mice increased with age (Fig. 2L-N). Thus, we conclude that RIP140 is a rate-limiting factor required for ductal development in the mammary epithelium. Analysis of mice at earlier time points indicated that there was no difference in the development of rudimentary ducts at day 24 (supplementary material Fig. S4A-B) and that the ducts had progressed to a similar extent at 5 weeks (supplementary material Fig. S4C,D,E) although more buds were evident at this stage (supplementary material Fig. S4C,D,F). In addition, we examined the effect of RIP140 overexpression on alveolar development during pregnancy. We observed that RIP140 Tg mice had larger and denser alveolar structures (Fig. 2P) compared with WT mice (Fig. 2O), indicating that RIP140 also influences alveologenesis. Examination of the mammary glands from RIP140 KO mice during pregnancy was not possible because these animals are infertile as a result of defective ovulation.

**RIP140 is required for oestrogen signalling in the mammary gland**

Given the importance of oestrogen and progesterone signalling in mammary gland development, we next examined the expression of their receptors, a number of their targets and other transcription factors associated with steroid hormone signalling. The expression of ERα mRNA and protein in mammary glands from RIP140 KO mice were similar to those in WT mice (Fig. 3A,B); however, the expression of a number of oestrogen targets, including Areg, Pgr, cyclin D1 (Ccnd1) and Gata3 were markedly reduced at both the mRNA and protein levels in the absence of RIP140. Consistent with these observations, there was a decrease in the expression of genes downstream of progesterone signalling, including Wnt4 and calcitonin (supplementary material Fig. S5A). It is noteworthy that the expression levels of many other genes that we monitored, including the ERα target gene c-Myc (Myc), the transcription factors c-Jun (Jun), cFos (Fos) and Sp1, the growth factor Igf2 and RANKL (Tnfsf11) were maintained in the RIP140 KO mammary glands (supplementary material Fig. S5A). Thus, expression of only a subset of oestrogen receptor target genes was reduced in the absence of RIP140 in the mammary gland. The reduction in Areg and Pgr expression suggests that oestrogen signalling is impaired in the absence of RIP140. This, together with the observed partially impaired progesterone signalling,
provides an explanation for the defect in primary duct formation and side-branching in RIP140 KO mice. Parallel gene expression analysis of RIP140 Tg and WT mice revealed similar levels of ERα, an increase in expression of Areg, Pgr, cyclin D1, Gata3 and a surge in the expression of Igf2 and RANKL in the RIP140 Tg mammary glands (supplementary material Fig. S5B). Immunocytochemical analysis of RANKL expression in mammary gland sections revealed that its expression was maintained in the absence of RIP140. In the RIP140 Tg mice, RANKL expression was more widespread, consistent with the increase in epithelial structures (supplementary material Fig. S6).

Further evidence to implicate RIP140 in oestrogen signalling in the mammary gland was obtained by examining the ability of oestrogen to rescue mammary gland development in ovariectomised WT and RIP140 KO animals. Ovariectomy was performed at 3 weeks of age and mice were implanted with slow-releasing oestradiol (E2) or placebo pellets for 21 days. Whereas placebo treatment in both genotypes did not promote ductal growth (Fig. 4B,D), E2 treatment rescued ductal development in WT (Fig. 4A) but not in RIP140 KO mice (Fig. 4C), which failed to show any ductal elongation, indicating that RIP140 is essential for oestrogen-induced ductal morphogenesis in the mammary gland at puberty. The efficacy of the E2 pellets in mice was confirmed by examining their uterine response; both genotypes exhibited larger uteri with water retention (supplementary material Fig. S7). Both RIP140 KO and RIP140 Tg mice have a normal oestrus cycle and analysis of circulating levels of oestradiol in both RIP140 KO and RIP140 Tg mice revealed no significant differences in their levels. There was a slight reduction in circulating prolactin in RIP140 KO mice and a corresponding increase in RIP140 Tg mice but the differences were not statistically significant (supplementary material Fig. S8).

RIP140KO mice contain the lacZ gene expression cassette in place of the RIP140 coding exon, which allows β-galactosidase activity to be used as a marker for RIP140 gene expression (White et al., 2000). RIP140 expression depicted by blue staining is localised in both the epithelial and the stromal compartments in the mammary gland (supplementary material Fig. S9). To identify the mammary gland compartment in which RIP140 expression is essential for ductal morphogenesis, tissue recombination experiments were performed. To determine whether RIP140 expression is required in the mammary epithelium, inguinal mammary fat pads of 21-day-old C57BL/6 WT animals were surgically cleared of endogenous epithelium and either maintained as controls (no epithelium injected) or injected with equal numbers of flow-sorted epithelial cells from WT or RIP140 KO donors (supplementary material Fig. S10A,B) in contralateral fat pads. After 6 weeks, an epithelial network was evident in those mice injected with WT epithelium (Fig. 5B) but not in those injected with RIP140 KO epithelium (Fig. 5C) or in control mice (Fig. 5A). The RIP140-null epithelium was unable to repopulate the fat pad even when the number of epithelial cells injected was doubled. Thus, we conclude that RIP140 expression is essential in the epithelium for ductal morphogenesis.

Next, we investigated the effect of pregnancy on the growth of the tissue recombinants by examining their morphology at parturition. Recombinants in which WT epithelium was transplanted generated differentiated alveolar structures throughout the fat pad (Fig. 5D). Interestingly, recombinants containing RIP140 KO epithelium also had the potential to generate differentiated alveolar outgrowths (Fig. 5E), albeit to a lesser extent than those containing WT epithelium. We were able to confirm that this engraftment was derived from the RIP140 KO epithelium because the outgrowths stained blue as a consequence of positive β-galactosidase activity (Fig. 5F). Thus, although the KO epithelium gave rise to thinner primary ducts and sparse alveolar structures upon transplantation (Fig. 5K,L) compared with WT epithelium (Fig. 5I,J), the lack of mammary gland development observed in the absence of RIP140 could be partially reversed in the presence of pregnancy-associated hormones, indicating that certain pathways are still conserved in RIP140 KO epithelial cells. To evaluate this further, we examined RANKL expression, which is a downstream effector of progesterone and prolactin signalling implicated in alveologenesis. We found that the expression of this mitogen was maintained in the alveolar structures generated in tissue recombinants with RIP140 KO epithelium (Fig. 5O,P), suggesting that a subset of pathways that promote alveologenesis do not require RIP140 expression. To determine whether stromal expression of RIP140 is required in mammary gland development, we injected mammary epithelial cells from WT animals into the cleared fat pads of 3-week-old RIP140 KO and control WT

**Fig. 3.** Expression analysis of the mammary glands. **A** and protein expression (western blots) **B** of mammary glands from mature WT and RIP140 KO mice (n=4). Error bars represent s.e.m. *P<0.05.

**Fig. 4.** Ductal elongation rescue using slow-release oestrogen pellets. **A-D** Mammary gland whole-mounts from 3-week-old, ovariectomised WT (A,B) and RIP140 KO (C,D) mice which were implanted with 21-day slow release oestradiol (A,C) or placebo (B,D) pellets (n=3). Scale bars: 2 mm.
mice. After 6 weeks, control WT recipients showed ductal elongation (Fig. 5G) but none of the RIP140 KO fat pads supported the growth of WT epithelium (Fig. 5H). Thus, the expression of RIP140 is essential in both the epithelial and the stromal compartments to support ductal morphogenesis of the mammary gland.

Q-PCR analysis of FACS-sorted mammary gland cells for expression of human RIP140 (hRIP140) (supplementary material Fig. S11A,B) indicated that RIP140 was overexpressed in both stroma and epithelium (luminal and basal cells). The effect of RIP140 overexpression in stroma and epithelium was examined in tissue recombinants during pubertal growth and differentiation during pregnancy. Whereas the control fat pads in which the endogenous epithelium was surgically removed did not show any ductal network after 6 weeks (supplementary material Fig. S11C), all the other tissue recombinants injected with sorted epithelium (supplementary material Fig. S10C,D), namely WT recipients injected with WT epithelium (supplementary material Fig. S11D), WT recipients injected with epithelium derived from RIP140 Tg glands (supplementary material Fig. S11E) and RIP140 Tg recipients injected with WT epithelium (supplementary material Fig. S11F), demonstrated ductal growth after 6 weeks. Quantification of the number of terminal end buds in each of the tissue recombinants revealed that both the RIP140 Tg epithelium and RIP140 Tg stroma promoted the formation of more terminal end buds compared with the WT (supplementary material Fig. S11G). Because RIP140 Tg mice do not usually survive through late pregnancy, a subset of tissue recombinants were analysed at day 15 of pregnancy. No morphological differences were evident in alveolar structures in WT mice that received WT (supplementary material Fig. S11H-H") or RIP140 Tg epithelium (supplementary material Fig. S11I-I"), however, recombinants that received RIP140 Tg epithelium exhibited slightly denser arrangement of alveolar structures compared with WT controls. Interestingly, after 15 days of pregnancy, RIP140 Tg fat pads that received WT epithelium were distinct from WT recipients (supplementary material Fig. S11J-J") and cross-sections revealed that they resembled lactating alveolar structures (supplementary material Fig. S11K"), albeit to a lesser extent than intact RIP140 Tg mammary glands at this stage (supplementary material Fig. S11L-K"'). Thus, we conclude that RIP140 overexpression in both the epithelium and the stroma contribute to the generation of densely arranged alveoli.

**RIP140 regulates mammary cell populations**

To examine the influence of RIP140 on the development and maintenance of subtypes of mammary cells, we used flow cytometry to quantify the different cell populations in WT, RIP140 KO and RIP140 Tg mice. Mammary glands from mature WT (C57BL/6)/ RIP140 KO and WT (FVB/N)/RIP140 Tg mice were dissected and dissociated into single-cell suspensions and immunostained to identify haematopoietic cells, endothelial cells and a fraction of the stromal cells so they could be excluded from the subsequent analysis. The remaining cells (termed Lin−) were also stained to detect expression of EpCAM, CD49f (Itga2−Mouse Genome Informatics) and CD49b (Itga2−Mouse Genome Informatics). Staining with this panel of markers permits resolution of stromal (EpCAM+) and epithelial (EpCAM+) cell populations. Epithelial cell populations were further resolved into basal (EpCAMlow/CD49fhigh) and luminal (EpCAMhigh/CD49flow) cells. Within the luminal cell population,
CD49b marker was used to resolve the differentiated luminal cells (CD49b') from the luminal progenitors (CD49b⁻) (Shehata et al., 2012). We observed that although there was no difference in the total number of stromal cells between the WT and RIP140 KO mice, the total number of epithelial cells was lower in RIP140 KO mice (Fig. 6A,B; supplementary material Fig. S12). Within the epithelium there was a reduction in both the basal and luminal cell populations in the RIP140 KO glands (Fig. 6C,D). Within the luminal compartment, both the differentiated and progenitor populations were reduced in the RIP140 KO mammary glands (Fig. 6E,F). Analysis of mammary cell populations from RIP140 Tg/WT mice revealed an increase in the epithelial cell numbers (Fig. 6I) but, interestingly, this increase was only due to an enhanced basal cell population (Fig. 6J,H). However, when the luminal cell population (Fig. 6K) was further resolved into luminal progenitors and differentiated cells there was an increase in the progenitor cell number (Fig. 6L) and a reduction in the number of differentiated cells (Fig. 6M) in the RIP140 Tg compared with the WT mammary glands. Thus, RIP140 is a key determinant in maintaining cell identity in the mammary epithelium.

We also performed in vitro colony forming cell (CFC) assays in order to validate the observation that there is a decreased number of progenitors in the RIP140 KO mice and an increased number in the RIP140 Tg mice compared with WT mice. Mammary glands isolated from RIP140 KO mice contain ~90% fewer CFCs than age-matched WT mammary glands (Fig. 6G), whereas the RIP140 Tg (Fig. 6N) glands demonstrated an approximate doubling of the number of CFCs compared with WT.

**RIP140 is recruited to the promoters and enhancers of several oestrogen-regulated genes along with EREs**

Given that our preliminary studies indicate that oestrogen signalling is impaired in RIP140-null mice leading to a reduction in the expression of several key oestrogen-regulated genes, we explored ERα and RIP140 binding to chromatin in mammary glands from 6-
week-old mice in which mammary epithelial development is underway. Using ChIP-seq analysis, we were able to obtain high quality data for ERα-chromatin interactions, which enabled an unbiased Q-PCR-based analysis of RIP140 binding events by interrogating the newly found ERα binding events for RIP140 presence. ERα-chromatin interactions were readily detected compared with input negative control as exemplified at the RIP140 locus (Fig. 7A). The 881 high quality chromatin interaction sites found for ERα are shown as a heatmap visualisation (Fig. 7B) and quantified as a 2D graph (Fig. 7C). Of these, 458 peaks were detected within 20 kb of gene promoters (supplementary material Table S2), which is the genomic distance within which most ERα-mediated gene regulation takes place (Fullwood et al., 2009). Next, the observed chromatin interaction patterns were analysed for enriched motifs. As expected, ESR-like motifs as well as SF1, Jun (Gaub et al., 1990) and TFAP2 (Woodfield et al., 2007) motifs were observed (Fig. 7D). We found only 6% of chromatin interactions of ERα at the promoters; the vast majority of binding events were found at enhancers and introns (Fig. 7E). Previously described ERα-responsive promoters as well as some newly identified ERα-associated enhancers were subsequently tested for RIP140 co-occupancy using ChIP-Q-PCR (Fig. 7F). We found that RIP140 was recruited with ERα on its own promoter (Fig. 7A,F) as well as promoters of the genes encoding several mammary gland mitogens and regulators, including Areg, Pgr, Ccnd1 and Gata3. Whereas RIP140 recruitment was detected on distal enhancer elements of several genes, e.g. Stat5a, Myc, Lif and Greb1, it was absent from several other proximal ERα binding sites, e.g. Cav1 and Vegfa, as well as enhancer regions for Areg, Pgr and Gata3 (Fig. 7F). Thus, although a sizeable number of ERα binding sites were co-occupied by RIP140 there were other sites for which RIP140 recruitment was not found, indicating selectivity in RIP140 binding. These data are consistent with the gene expression of Areg, Pgr, Ccnd1 and Gata3 in RIP140 KO and RIP140 Tg (H) mammary glands (n=4). *P<0.05. Error bars represent s.e.m.
binding is dispensable for regulation from this site. To validate further the role of RIP140 in gene regulation on some of the newly identified sites, we compared gene expression in RIP140 KO, RIP140 Tg and WT mice. Expression of Stat5a, RIP140 and Lifr was modulated by RIP140 whereas Cav1 expression was maintained in both the RIP140 KO and RIP140 Tg, indicating that it is not a RIP140 target despite ERFa recruitment (Fig. 7G,H). Selective binding might be determined by the architecture (transcription factor binding elements) of the DNA sequence but, importantly, RIP140 together with ERFa regulates the transcription of mitogenic signals eminating from the mammary gland.

**DISCUSSION**

In this article, we demonstrate that RIP140 is an important mediator of oestrogen-induced mammary epithelial cell proliferation as loss of RIP140 severely impairs the formation of TEBs and the ductal elongation and branching morphogenesis that occurs during puberty. This phenotype mirrors that observed in mammary glands in ER KO mice (Mallepell et al., 2006) and thus supports a role for RIP140 in oestrogen-mediated ductal development. This phenomenon appears to be intrinsic to the mammary epithelial cells and is not due to systemic effects, such as disruption of the hypothalamic pituitary axis (Leonardsson et al., 2002). Tissue recombination experiments clearly demonstrate that RIP140 KO epithelium is unable to repopulate the normal mammary fat pad, even in a WT host animal. This observation is in agreement with our previous studies that demonstrate that infertility in the RIP140 KO females could be reversed by transplanting WT ovaries, indicating an intact hypothalamic pituitary axis (Leonardsson et al., 2002).

The molecular mechanism by which RIP140 appears to function in the mammary gland is not via transcriptional regulation of ERFa expression; instead, RIP140 appears to modulate the expression of several ERFa target genes, such as Areg, Pgr, Cond1 and Stat5a, by functioning as a co-factor that is recruited with ERFa to their promoters/enhancers. When RIP140 expression is ablated, there is loss of expression of Areg and Pgr and this results in profound developmental defects because these factors are essential for subsequent mammary development (Lydon et al., 1995; Ismail et al., 2002; Ciarloni et al., 2007). In contrast to the impaired mammary gland development observed in the RIP140 KO mice, overexpression of RIP140 results in increased side branching and development of alveolar bud-like structures along with increased cell division, which in some cases, results in epithelial hyperplasia and the formation of TEB-like structures in older (e.g. 5-month-old) transgenic animals. The observed hyperplastic structures can be described as simple ductal hyperplasia and are potential tumour precursors (Medina, 1976); however, we were unable to extend these studies to test this directly as RIP140 animals die prematurely because of heart defects (Fritah et al., 2010).

Tissue recombination experiments also demonstrated that RIP140 expression is required in the mammary stroma for ductal development to occur. The requirement of RIP140 indicates that although there are similarities in the phenotype of ER KO and RIP140 KO animals, there are also important differences as ERFa expression is not required in the stroma for normal mammary development (Mallepell et al., 2006). A comparison of the distribution of ERFs and RIP140 shows that, despite there being an overlap in their expression in the body cells and luminal cells in the TEBs and mature ducts, respectively, RIP140 is expressed in cap cells and the basal cells, which are devoid of ERFa (supplementary material Fig. S13). Gene expression analysis of purified subsets of mouse mammary cell populations (Shehata et al., 2012) reveals that several nuclear receptors and transcription factors with which RIP140 is known to act as a co-regulator have a differential distribution within these subpopulations (supplementary material Table S3; Fig. S14). As RIP140 is expressed both in the stroma and epithelium, as are several of its potential nuclear receptor partners, it is conceivable that RIP140 could drive transcription of gene targets through several nuclear receptors, including ERFa. If so, this could explain why although ERFa expression is required only in the epithelium, the expression of RIP140 is essential both in the mammary epithelium and the stroma. It is somewhat surprising that the RIP140 KO epithelium, which failed to show puberal ductal elongation, could still undergo alveolar differentiation; however, the alveoli generated were smaller and sparser than those obtained with WT controls, indicating that RIP140 is important for the generation of factors that influence cell proliferation and maintenance during pregnancy. The observation that expression levels of RANKL in tissue recombinants derived from RIP140 KO epithelium are comparable to those in the WT indicates that certain pathways that drive alveolar differentiation (Fata et al., 2000; Fernandez-Valdivia et al., 2009) are conserved in the RIP140 KO epithelium.

Mammary stem cells and certain progenitor cells within the mammary epithelium do not express ERFa or Pgr (Asselin-Labat et al., 2006), but yet are highly sensitive to oestrogen and progesterone (Asselin-Labat et al., 2010; Joshi et al., 2010). It is now emerging that steroid hormones, in addition to having direct effects on relatively mature steroid receptor-expressing progenitor cells, also strongly influence mammary stem and steroid hormone-negative progenitor cells via paracrine interactions that are mediated by the RANK ligands Wnt4 and Areg (Brisken et al., 2000; Ciarloni et al., 2007; Beleut et al., 2010). Thus, the loss of expression of some of these paracrine factors in RIP140 KO mice probably accounts for the reduction in the number of stem and progenitor cells observed in the mammary glands of these mice. Similarly, the surge in RANKL expression in the RIP140 Tg glands, along with other factors, including Stat5 (Furth et al., 2011), could account for the increased number of luminal progenitors and basal cells. It is noteworthy that although expression of RANKL and Igf2 was unaltered in RIP140 KO mice, their expression was greatly amplified in RIP140 Tg animals compared with the WT mice, indicating that this might be a consequence of indirect effects of RIP140 overexpression.

Several co-factors, such as steroid receptor co-activator 1 (SRC-1; Ncoa1 – Mouse Genome Informatics), steroid receptor co-activator 3 (SRC-3; Ncoa3 – Mouse Genome Informatics), CBP/p300 interacting transactivator 1 (Cited1) and mediator-1 (Med1), have been shown to play a role in mammary gland development and breast cancer (Han et al., 2006; Howlin et al., 2006; Jiang et al., 2010), and the binding profiles of these co-factors identify specific transcriptional networks that influence clinical outcome in breast cancer (Zwart et al., 2011). Here, we demonstrate that RIP140 is a co-factor for ERFa and that it regulates ductal formation during mammary gland development, but it might also potentially act as a co-factor for other nuclear receptors and transcription factors. RIP140 is a known co-factor for multiple other nuclear receptors, including PPARg (PPARG), farnesoid X receptor (FXR; NR1H4) and estrogen-related receptors (Christian et al., 2006), all of which have been implicated in breast cancer progression (Fenner and Elstner, 2005; Riggins et al., 2010; Giordano et al., 2011). Further analysis of the mechanisms of action of RIP140 in breast cancer will provide new insights and might point towards potential pathways for the development of new strategies for breast cancer treatment.
Acknowledgements
We thank Dr Amel Saadi, Dr Mona Shehata and Rajeshkar Girradi for valuable technical advice for performing the mammary gland tissue recombinants and FACS analysis. We also thank Mr Reece Williams and Ms Maeve Troy for their support in the animal facility. In addition we thank Ron Kerkhoven, Arno Velds and Marja Nieuwland for Solexa sequencing. We are grateful to Prof. Daniel Medina for expert advice on the mammary hyperplastic structures found in the RIP140 Tg mice, and Drs Simak Ali and Laki Boulwela for critical reading of the manuscript.

Funding
This work was supported by a Wellcome Trust grant [0792002/06/2: to J.N., J.H.S., A.P. and M.G.P.]; a Biotechnology and Biological Sciences Research Council grant [B/B/C5043271 to M.R.M. and M.G.P.]; and the Genesis Research Trust. J.S. is supported by Cancer Research UK, The University of Cambridge and Hutchison Whampoa Limited. Deposited in PMC for immediate release.

Competing interests statement
The authors declare no competing financial interests.

Author contributions
J.N. and M.G.P. conceived the project. J.N., J.H.S., M.P., W.Z., J.S. and M.G.P. carried out the research. J.S. critically reviewed the manuscript. J.N. and M.G.P. wrote the manuscript.

Supplementary material
Supplementary material available online at http://dev.biologists.org lookup/suppl/doi:10.1242/dev.085720/DC1

References


Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.

Ciona intestinalis, 5455-5460.


Fig. S1. Ductal network in 5-month-old RIP140 KO mice. (A-B′) Mammary gland whole-mounts from representative RIP140 heterozygous (RIP140 Het) (A) and RIP140 KO (B) mice. RIP140 KO mice show a sparse ductal tree compared with the extensive ductal network seen in the RIP140 Het. A′ and B′ show magnified images of the boxed areas in A and B, respectively (n=2). Scale bars: 1 mm.

Fig. S2. Analysis of RIP140 over expressing transgenic mammary glands. (A) Q-PCR analysis shows over expressed human RIP140 (hRIP140) in the mammary glands from RIP140 transgenic mice. (B) Western blots using RIP140 (1:1000; 6D7, in-house monoclonal) and β-actin (1:5000; Abcam, Cambridge, MA) primary antibodies, show increased RIP140 expression in the mammary glands of the RIP140 transgenic mice (n=3). Error bars represent s.e.m. **P<0.005.
Fig. S3. Mammary gland histology. H&E-stained cross-sections through the mammary glands of 3-, 4- and 5-month-old WT and RIP140 Tg mice showing increased hyper budding in RIP140 Tg mice (n=3). Scale bars: 200 μm.
Fig. S4. RIP140 Tg mammary gland development. (A-D’) Whole-mounts of 24-day-old WT (A) and RIP140 Tg (B), and 5-week-old WT (C) and RIP140 Tg (D) mice. A’, B’, C’ and D’ are magnified images of the boxed areas in A, B, C and D, respectively. (E) Distance travelled by the ductal network from the root of the epithelium to the tip of the terminal end buds in 5-week-old WT and RIP140 Tg mice. (F) Quantification of budding points in 5-week-old WT and RIP140 Tg mice (n=5).***P<0.0001. Error bars represent s.e.m. Scale bars: 1 mm.
Fig. S5. Mammary gland gene expression. Quantitative RT-PCR analysis of gene expression in mammary glands of WT/RIP140 KO (A) and WT/RIP140 Tg (B) mice (n=4). *P<0.05. Error bars represent s.e.m.
Fig. S6. Immunocytochemical analysis of RANKL expression in adult (virgin) mice. (A-C) RANKL staining (brown) in WT (C57BL/6) (A) and RIP140 KO (B) and the no primary antibody control (C). (D-F) RANKL staining in WT (FVB/N) (D) and RIP140 Tg (E) and the no primary antibody control (F). (n=3). Scale bars: 50 μm.

Fig. S7. Efficacy of estradiol treatment in vivo. (A-D) Uteri from WT (A,B) and RIP140 KO (C,D) mice treated with 21-day slow release oestradiol (B,D) or placebo (A,C) pellets. Mice treated with oestradiol pellets showed heavier uteri with water retention (n=3).
Fig. S8. Hormone measurements. (A-D) Serum estradiol (A,B) and prolactin (C,D) concentration in individual 8- to 12-week-old virgin WT/RIP140 KO (C57BL/6) (A,C) and WT/RIP140 Tg (FVB/N) (B,D) mice. Horizontal line represents the mean value.
Fig. S9. Mammary gland sections from RIP140 KO mice stained for β-galactosidase activity. (A,B) Blue staining depicts RIP140 expression both in the epithelium (epi) and stroma (str) (A). Staining with nuclear fast red (a counterstain) helps highlight RIP140 expression in both the luminal (Lu) and the basal (Ba) layers of the epithelium (B). Scale bars: 50 µm.
Fig. S10. Purification of epithelial (EpCAM⁺) cells from single cell suspensions of mouse mammary cells. Histograms show EpCAM-expressing cells (P5) in total mammary cell preparations isolated from WT (C57BL/6) (A), RIP140 KO (B), WT (FVB/N) (C) and RIP140 Tg (D) mice. These purified epithelial cells were sorted and injected as donor cells in the tissue recombinant experiments.
Fig. S11. Tissue recombination experiments. (A) Sorting strategy for mammary cell populations for gene expression analysis. Cell population in black (P6) represents stromal, in blue (P7) luminal and in red (P8) basal cells. (B) Q-PCR for RIP140 over expression (hRIP140) in mammary cell populations (n=4). (C-F) Tissue recombinants for pubertal growth in the mammary gland. (C) Representative image of a fat pad cleared of endogenous epithelium but not injected with donor epithelial cells. (D,E) Fat pads cleared of endogenous epithelium from 3-week-old WT mice, which were either injected with epithelium from WT (D) or RIP140 Tg (E) donors. (F) Three-week-old RIP140 Tg mice injected with epithelium from WT donors after removal of endogenous epithelium. Images represent recipient fat pads after 6 weeks of donor epithelium injections. (G) Quantification of number of TEBs in D-F. (H-J) Tissue recombinants at day 15 of pregnancy. (H,I) Fat pads from WT mice injected with epithelium from WT (H) or RIP140 Tg (I) donor mice. (J) Fat pad from RIP140 Tg mice injected with epithelium from WT donor. (K) Representative whole-mount of an intact RIP140 Tg mouse at day 15 of pregnancy (n=3). *P<0.05. (H′,I′,J′,K′) Magnified images of boxed area in from H,I,J,K, respectively. (H″,I″,J″,K″) Cross-sections through H,I,J,K, respectively. Error bars represent s.e.m. Scale bars: 1 mm in C-F,H-K; 100 μm in H′,I′,J′,K′.
Fig. S12. Mammary gland cell populations. Histograms representing number of cells in different cell populations obtained from single cell suspensions of WT/RIP140 KO (A) and WT/RIP140 Tg (B) mammary glands. *P<0.05. Error bars represent s.e.m.
Fig. S13. ERα and RIP140 co-localization analysis. (A-D) Immunocytochemical expression (brown) of ERα (A,B) and RIP140 (C,D) in mammary gland sections showing expression in the terminal end buds (A,C), epithelial ducts (B,D) and stroma (Str). Sections are counterstained with Haematoxylin to highlight nuclei. In the TEBs, ERα expression is absent in the cap cells, which are positive for RIP140. In the mature ducts, RIP140 is expressed both in the luminal (Lu) and basal (Ba) layers. (E) RIP140 KO mammary gland section stained with RIP140 antibody. Scale bars: 50 μm.
Fig. S14. Q-PCR analysis of gene expression for RIP140 and several nuclear receptors and transcription factors in sorted mammary cell populations from adult virgin WT mice. Error bars represent s.e.m.
<table>
<thead>
<tr>
<th>Q-PCR primer name</th>
<th>Primer sequences (5'-3')</th>
</tr>
</thead>
<tbody>
<tr>
<td>ERα F:</td>
<td>CCTCCCGCCTTCTACAGGT R: CACACGGCAGACATGGAG</td>
</tr>
<tr>
<td>Areg F:</td>
<td>TCCGGCTATATATAGATTATGCAGTC</td>
</tr>
<tr>
<td>Pgr F:</td>
<td>GGTTAGAGGATCGTCAAGCG</td>
</tr>
<tr>
<td>Ccen1 F:</td>
<td>CGAGAAAGGCGACACGAGGT</td>
</tr>
<tr>
<td>Gata3 F:</td>
<td>AGTGGGAGAGGGGTGTTGTAT</td>
</tr>
<tr>
<td>RIP140 F:</td>
<td>CCCCAGTACCAACAGGACTAC</td>
</tr>
<tr>
<td>Stat5a F:</td>
<td>TCCCCATCTATGTTGCTTTTG</td>
</tr>
<tr>
<td>Lifr F:</td>
<td>TACGTCGGCAGACTCGATATT</td>
</tr>
<tr>
<td>Cav1 F:</td>
<td>GCGACCCCAAGCATCTCAA</td>
</tr>
<tr>
<td>cJun F:</td>
<td>CGGACCGTTCTATGACTGCAA</td>
</tr>
<tr>
<td>cFos F:</td>
<td>CCTGCCCCTTCTCAACGAC</td>
</tr>
<tr>
<td>Sp1 F:</td>
<td>CGGCCCTTTTCTCAACGAGC</td>
</tr>
<tr>
<td>RANKL F:</td>
<td>TGACTTCTTTGAGCGAGATG</td>
</tr>
<tr>
<td>FXR F:</td>
<td>CACGAAAGTCAGATTGCTTTGC</td>
</tr>
<tr>
<td>LRH1 F:</td>
<td>TGCATGCAGAAAAAGCCTAAG</td>
</tr>
<tr>
<td>RARG F:</td>
<td>TGACTGGGAGGGCTGGGTA</td>
</tr>
<tr>
<td>RARB F:</td>
<td>ACCCCAGCGAGACTGGGCTAC</td>
</tr>
<tr>
<td>PPARG F:</td>
<td>CCCCCCTCTCTAGCAAGATC</td>
</tr>
<tr>
<td>VDR F:</td>
<td>GACAGGAGCAGCTAAGC</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ChIP Primer Name</th>
<th>Primer sequences (5'-3')</th>
</tr>
</thead>
<tbody>
<tr>
<td>rip140 prom F:</td>
<td>GTCTCTCTTTCTCCCGTTTTC</td>
</tr>
<tr>
<td>areg Prom F:</td>
<td>CCGGTTGGAACAAATGAGAAACT</td>
</tr>
<tr>
<td>areg Enh F:</td>
<td>AAGATGGGACGACGCTTTTTT</td>
</tr>
<tr>
<td>pgr Prom F:</td>
<td>GGTTAGGGAGGCTGGAGC</td>
</tr>
<tr>
<td>pgr Enh F:</td>
<td>GTGGTGAGGAGGCTGGAGC</td>
</tr>
<tr>
<td>cCen1 Prom F:</td>
<td>CCCCCAGCAGGAGATG</td>
</tr>
<tr>
<td>gata3 Prom F:</td>
<td>GGGAGGATGGGAGGCTGGAGC</td>
</tr>
<tr>
<td>gata3 Enh F:</td>
<td>GAGATGGGAGGCTGGAGC</td>
</tr>
<tr>
<td>stat5a F:</td>
<td>GTTCAAAATGAGGCAGAAATT</td>
</tr>
<tr>
<td>cCed6 F:</td>
<td>GTGACGTCAATGGGAGGCT</td>
</tr>
<tr>
<td>myc enh F:</td>
<td>GTTGGAGGAGGCTGGAGC</td>
</tr>
<tr>
<td>cued6 F:</td>
<td>TTGGTTGAGGAGGCTGGAGC</td>
</tr>
<tr>
<td>lif F:</td>
<td>GAGAGCCAGGATGCTAGGA</td>
</tr>
<tr>
<td>greb1 F:</td>
<td>TCTCTGGGAGGCTGGAGC</td>
</tr>
<tr>
<td>lpg F:</td>
<td>TTGGTTGAGGAGGCTGGAGC</td>
</tr>
<tr>
<td>met2a F:</td>
<td>GTGAGGAGGCTGGAGC</td>
</tr>
<tr>
<td>cav1 F:</td>
<td>CCCCCGAGCAGGCTGGAGC</td>
</tr>
<tr>
<td>vegf F:</td>
<td>AGAAGAGCAAGGATGCTAGGAGC</td>
</tr>
<tr>
<td>bGlobin F:</td>
<td>CCTGCCCCCCTCTATCTCTT</td>
</tr>
</tbody>
</table>

F, forward primer; R, reverse primer
Table S2. List of 458 genes for which ERα binding could be detected within 20 kb of gene promoters.

<table>
<thead>
<tr>
<th>Entrez ID</th>
<th>Gene symbol</th>
<th>Gene description</th>
<th>ER– progenitor</th>
<th>ER+ progenitor</th>
<th>Differentiated luminal</th>
<th>Basal</th>
<th>Stromal</th>
</tr>
</thead>
<tbody>
<tr>
<td>2103</td>
<td>ESRRB</td>
<td>Estrogen-related receptor beta</td>
<td>5.325514728</td>
<td>6.45856139</td>
<td>6.606453279</td>
<td>5.365730097</td>
<td>5.25737677</td>
</tr>
<tr>
<td>2104</td>
<td>ESRRG</td>
<td>Estrogen-related receptor gamma</td>
<td>5.254721211</td>
<td>5.353738986</td>
<td>5.66897559</td>
<td>5.18125953</td>
<td>5.263388265</td>
</tr>
<tr>
<td>7421</td>
<td>VDR</td>
<td>Vitamin D (1,25-dihydroxyvitamin D3) receptor</td>
<td>6.443922757</td>
<td>5.753070844</td>
<td>5.661924723</td>
<td>6.18300242</td>
<td>5.136685212</td>
</tr>
<tr>
<td>6097</td>
<td>RORC</td>
<td>RAR-related orphan receptor C</td>
<td>6.104929531</td>
<td>5.465568827</td>
<td>5.719564933</td>
<td>5.391660104</td>
<td>5.095232079</td>
</tr>
<tr>
<td>5468</td>
<td>PPARG</td>
<td>Peroxisome proliferator-activated receptor gamma</td>
<td>5.319266772</td>
<td>5.401434715</td>
<td>5.670253622</td>
<td>5.512429536</td>
<td>6.429797525</td>
</tr>
<tr>
<td>5915</td>
<td>RARB</td>
<td>Retinoic acid receptor, beta</td>
<td>5.032788316</td>
<td>5.147905268</td>
<td>5.145224064</td>
<td>5.179409455</td>
<td>5.29418781</td>
</tr>
<tr>
<td>5916</td>
<td>RARG</td>
<td>Retinoic acid receptor, gamma</td>
<td>5.45835644</td>
<td>5.270686782</td>
<td>5.650083338</td>
<td>5.348901578</td>
<td>5.514703504</td>
</tr>
<tr>
<td>3725</td>
<td>JUN</td>
<td>Jun oncogene</td>
<td>7.801161199</td>
<td>7.271524941</td>
<td>7.241651942</td>
<td>7.463239551</td>
<td>6.995269918</td>
</tr>
<tr>
<td>2494</td>
<td>NR5A2</td>
<td>Nuclear receptor subfamily 5, group A, member 2</td>
<td>5.558124566</td>
<td>6.156559978</td>
<td>5.531169896</td>
<td>5.746186332</td>
<td>5.452759444</td>
</tr>
<tr>
<td>2099</td>
<td>ESR1</td>
<td>Estrogen receptor 1</td>
<td>5.640602984</td>
<td>6.888940536</td>
<td>6.867860909</td>
<td>5.408619722</td>
<td>5.713373377</td>
</tr>
<tr>
<td>9971</td>
<td>NR1H4</td>
<td>Nuclear receptor subfamily 1, group H, member 4</td>
<td>5.101617011</td>
<td>5.127743796</td>
<td>5.12201353</td>
<td>5.146607576</td>
<td>5.575165887</td>
</tr>
</tbody>
</table>

Table S3. Data mined from a microarray of gene expression signatures from mouse mammary cell populations, showing differential expression of nuclear receptors and transcription factors, which RIP140 could potentially co-regulate. Centroids of gene expression for each cell subpopulation were built from the union set of top differentially expressed genes between each pair of cell subtypes. To identify differentially expressed genes, genes were first filtered according to variability and then the limma R package was used to rank them according to differential expression using B-statistics. The False Discovery Rate (FDR) was estimated using the q-value R package. In order to avoid skewing the number of centroid genes to specific cell types, top 250 up- and top 250 downregulated genes were selected in each cell-type comparison. All of these passed FDR corrected P-values <0.05. Data taken from Shehata et al. (Shehata et al., 2012).